Anti-envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection.
antibodies
hepatitis C virus
highly exposed seronegative
humoral immunity
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
received:
25
03
2020
accepted:
11
05
2020
pubmed:
5
6
2020
medline:
1
9
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
In rare cases, individuals with a history of long-term injecting drug use remain seronegative and aviraemic, despite prolonged and likely repeated exposure to Hepatitis C virus (HCV) through high-risk behaviour. We describe anti-HCV Envelope (E) antibody responses in a prospective cohort of carefully defined highly exposed but uninfected subjects (HESN) and comparison subjects who were also high risk and uninfected, but rapidly became HCV infected (Incident). Longitudinally collected samples from HESN cases (n = 22) were compared to Incident controls (n = 22). IgG, IgM and IgA from sera were tested by ELISA to genotype 1a and 3a E glycoproteins, and recombinant genotype 1a E2 antigen. IgG subclass isotyping was performed for those positive for IgG. Virus-neutralizing activity was assessed on HCV pseudoparticles, and HCV E-specific B cells analysed using flow cytometry. A significant minority of HESN cases (n = 10; 45%) had anti-E, predominantly in the IgG2 subclass, which was not found in the pre-infection time point of the Incident cases (n = 1; 5%). A subset of the HESN subjects also had neutralizing activity and HCV-specific B cells detected significantly more than Incident cases pre-infection. In conclusion, the HESN phenotype is associated with IgG2 anti-E antibodies, neutralization activity and HCV E-specific memory B cells. These findings suggest that HESN subjects may be resistant to HCV infection through humoral immune-mediated mechanisms.
Substances chimiques
Hepatitis C Antibodies
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1012-1021Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2:161-176.
Mehta SH, Astemborski J, Kirk GD, et al. Changes in blood-borne infection risk among injection drug users. J Infect Dis. 2011;203:587-594.
Kim DY, Ahn SH, Han KH. Emerging therapies for hepatitis C. Gut Liv. 2014;8:471-479.
Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver Int. 2013;33(Suppl 1):68-79.
Mina MM, Luciani F, Cameron B, et al. Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infect Dis. 2015;15:451-460.
Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore). 1995;74:212-220.
Thurairajah PH, Hegazy D, Chokshi S, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis. 2008;198:1749-1755.
Grebely J, Prins M, Hellard M, et al. International Collaboration of Incident HIV, Hepatitis CiIC. Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis. 2012;12:408-414.
Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003;197:633-642.
Major ME, Dahari H, Mihalik K, et al. Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees. Hepatology. 2004;39:1709-1720.
Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med. 2001;194:1395-1406.
Swann RE, Mandalou P, Robinson MW, et al. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. J Viral Hepat. 2016;23:873-880.
Bartosch B, Cosset FL. Cell entry of hepatitis C virus. Virology. 2006;348:1-12.
Osburn WO, Fisher BE, Dowd KA, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology. 2010;138:315-324.
Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012;205:763-771.
Al-Sherbiny M, Osman A, Mohamed N, et al. Exposure to hepatitis C virus induces cellular immune responses without detectable viremia or seroconversion. Am J Trop Med Hyg. 2005;73:44-49.
Della Bella S, Riva A, Tanzi E, et al. Hepatitis C virus-specific reactivity of CD4+-lymphocytes in children born from HCV-infected women. J Hepatol. 2005;43:394-402. (eng).
Kamal SM, Amin A, Madwar M, et al. Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients. J Virol. 2004;78:12252-12258.
Koziel MJ, Wong DK, Dudley D, Houghton M, Walker BD. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis. 1997;176:859-866.
Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Hepatology. 2010;52:1581-1589.
Warshow UM, Riva A, Hegazy D, et al. Cytokine profiles in high risk injection drug users suggests innate as opposed to adaptive immunity in apparent resistance to hepatitis C virus infection. J Viral Hepat. 2012;19:501-508.
Cunningham EB, Hajarizadeh B, Amin J, et al. Investigators HI-p. Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. Int J Drug Policy. 2018;54:18-25.
Luciani F, Bretana NA, Teutsch S, et al. A prospective study of hepatitis C incidence in Australian prisoners. Addiction. 2014;109:1695-1706.
Teutsch S, Luciani F, Scheuer N, et al. Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohort. BMC Public Health. 2010;10:633.
Dyer WB, Pett SL, Sullivan JS, et al. Substantial improvements in performance indicators achieved in a peripheral blood mononuclear cell cryopreservation quality assurance program using single donor samples. Clin Vaccine Immunol. 2007;14:52-59.
D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J. 2000;139:272-281.
Boileau C, Bruneau J, Al-Nachawati H, Lamothe F, Vincelette J. A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials. J Acquir Immune Defic Syndr. 2005;39:489-495.
Mina MM, Cameron B, Luciani F, Vollmer-Conna U, Lloyd AR. investigators HI-p. Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users. J Viral Hepat. 2016;23:464-472.
Sugden PB, Cameron B, Luciani F, Lloyd AR, Investigators H. Exploration of genetically determined resistance against hepatitis C infection in high-risk injecting drug users. J Viral Hepat. 2014;21:e65-73.
Tarr AW, Owsianka AM, Szwejk A, Ball JK, Patel AH. Cloning, expression, and functional analysis of patient-derived hepatitis C virus glycoproteins. Methods Mol Biol. 2007;379:177-197.
Urbanowicz RA, McClure CP, King B, Mason CP, Ball JK, Tarr AW. Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. J Gen Virol. 2016;97:2265-2279.
Patel AH, Wood J, Penin F, Dubuisson J, McKeating JA. Construction and characterization of chimeric hepatitis C virus E2 glycoproteins: analysis of regions critical for glycoprotein aggregation and CD81 binding. J Gen Virol. 2000;81:2873-2883.
Wu BR, Eltahla AA, Keoshkerian E, et al. A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. J Immunol Methods. 2019;472:65-74.
Walker MR, Leung P, Eltahla AA, et al. Clearance of hepatitis C virus is associated with early and potent but narrowly-directed. Envelope-specific antibodies. Sci Rep. 2019;9:13300.
Cramp ME, Carucci P, Rossol S, et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut. 1999;44:424-429.
Freeman AJ, Ffrench RA, Post JJ, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis. 2004;190:1093-1097. (eng).
Pestka JM, Zeisel MB, Blaser E, et al. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A. 2007;104:6025-6030.
Osburn WO, Snider AE, Wells BL, et al. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology. 2014;59:2140-2151.
Bailey JR, Flyak AI, Cohen VJ, et al. Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance. JCI Insight. 2017;2(9):e92872.
Walker MR, Eltahla AA, Mina MM, Li H, Lloyd AR, Bull RA. Envelope-specific IgG3 and IgG1 responses are associated with clearance of acute hepatitis C virus infection. Viruses. 2020;12(1):75.
Freeman AJ, Zekry A, Whybin LR, et al. Hepatitis C prevalence among Australian injecting drug users in the 1970s and profiles of virus genotypes in the 1970s and 1990s. Med J Aust. 1990s;172:588-591.
Walker MR, Li H, Teutsch S, et al. Incident hepatitis C virus genotype distribution and multiple infection in Australian Prisons. J Clin Microbiol. 2016;54:1855-1861.
Murphy SL, Li H, Mingozzi F, et al. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J Med Virol. 2009;81:65-74.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.
Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med. 2002;196:303-310.
Vidarsson G, Stemerding AM, Stapleton NM, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood. 2006;108:3573-3579.
Morel A, Passot C, Arnoult C, et al. The neonatal Fc receptor does not modulate hepatitis C virus neutralization. J Gen Virol. 2015;96:1062-1066.
Hanafiah M, Prastowo J, Hartati S, Aliza D, Nurcahyo RW. Detection of Toxoplasma gondii copro-prevalence by polymerase chain reaction using repetitive 529 bp gene in feces of pet cats (Felis catus) in Yogyakarta, Indonesia. Vet World. 2018;11:1338-1343.